Checking distributional assumptions for pharmacokinetic summary statistics based on simulations with compartmental models. Issue 5 (3rd September 2017)

• Record Type: Journal Article
• Authors: Shen, Meiyu; Russek-Cohen, Estelle; Slud, Eric V.
• Is Part Of: Journal of biopharmaceutical statistics. Volume 27:Issue 5(2017)
• Page Start: 756
• Page End: 772
• Publication Date: 2017-09-03
• Subjects: Bioequivalence -- distributional assumption -- normality -- pharmacokinetic modeling; Pharmacy -- Statistical methods -- Periodicals; Drugs -- Testing -- Statistical methods -- Periodicals; Biometry -- Periodicals; Biopharmaceutics -- Periodicals; Pharmacokinetics -- Periodicals; 615.19
• DOI: 10.1080/10543406.2016.1222535
• Languages: English
• ISSNs: 1054-3406

Abstract

ABSTRACT: Bioequivalence (BE) studies are an essential part of the evaluation of generic drugs. The most common in vivo BE study design is the two-period two-treatment crossover design. AUC (area under the concentration–time curve) and Cmax (maximum concentration) are obtained from the observed concentration–time profiles for each subject from each treatment under each sequence. In the BE evaluation of pharmacokinetic crossover studies, the normality of the univariate response variable, e.g. log( AUC ) 1 or log( Cmax ), is often assumed in the literature without much evidence. Therefore, we investigate the distributional assumption of the normality of response variables, log( AUC ) and log( Cmax ), by simulating concentration–time profiles from two-stage pharmacokinetic models (commonly used in pharmacokinetic research) for a wide range of pharmacokinetic parameters and measurement error structures. Our simulations show that, under reasonable distributional assumptions on the pharmacokinetic parameters, log( AUC ) has heavy tails and log( Cmax ) is skewed. Sensitivity analyses are conducted to investigate how the distribution of the standardized log( AUC ) (or the standardized log( Cmax )) for a large number of simulated subjects deviates from normality if distributions of errors in the pharmacokinetic model for plasma concentrations deviate from normality and if the plasma concentration can be described by different compartmental models.